

# **Executive Officer Notice:**

## **Funding Continuous Glucose Monitoring Systems through the Ontario Drug Benefit Program**

**July 24, 2025**

**Effective July 31, 2025, Ontario will fund Dexcom G7<sup>®</sup> Continuous Glucose Monitoring (CGM) System through the Ontario Drug Benefit (ODB) program.**

The purpose of this notice is to provide information to dispensers on Health Network System (HNS) claim submissions and reimbursement for CGM systems designated as listed substances on the Formulary under the *Ontario Drug Benefit Act* (ODBA). This notice serves to communicate a Ministry of Health (ministry) policy that dispensers must adhere to in accordance with section 3.2 of the HNS Subscription Agreement.

### **Overview – Dexcom G7<sup>®</sup> Sensors and Dexcom G7<sup>®</sup> Receivers**

The Dexcom G7<sup>®</sup> is a real-time Continuous Glucose Monitoring (rtCGM) system. It will be funded for ODB program recipients on insulin therapy.

It has two components:

1. Dexcom G7<sup>®</sup> Sensor (1-pack)
2. Dexcom G7<sup>®</sup> Receiver (or via the Dexcom G7<sup>®</sup> android CGM app or the Dexcom G7<sup>®</sup> iOS CGM app)

Each Dexcom G7<sup>®</sup> Sensor measures glucose for 10 days plus a 12-hour grace period.

### **Reimbursement Criteria**

All ODB program recipients on insulin therapy for diabetes who have a valid prescription from a physician or nurse practitioner for CGM sensors and/or receivers/readers listed on

the Formulary are eligible to receive the Formulary-listed CGM sensors and/or receivers/readers that have been prescribed free-of-charge, subject to the Restrictions below and any applicable co-payment.

### **Payment**

Claims for Dexcom G7® Sensors and Dexcom G7® Receivers listed on the Formulary will be paid by the ministry. For each valid claim submitted, dispensers are eligible to be paid in accordance with the following formula\*:

Amount MOH Pays + applicable mark-up + applicable dispensing fee – any applicable co-payment

Where,

“Amount MOH Pays” is the price listed on the Formulary for the CGM product;

“Mark-up” is the mark-up described in section 5.1 of the Ontario Drug Programs Reference Manual based on the cost of the CGM product being dispensed;

“Dispensing Fee” is the dispensing fee set out in section 13 of O. Reg. 201/96 under the ODBA (in the case of a pharmacy) or section 17 of O. Reg. 201/96 (in the case of a dispensing physician), the payment of which is subject to the conditions set out in section 18 of O. Reg. 201/96 and section 6.16 of the Ontario Drug Programs Reference Manual;

“Co-payment” is the co-payment described in section 20.1 or 20.2 of O. Reg. 201/96 under the ODBA, if applicable.

\*the amount paid for claims is also subject to any deductible that applies under O. Reg. 201/96, as applicable

### **Pharmacy Billing Procedure**

Claims must be submitted online through the HNS. The claim submission follows the normal process for submitting claims through the HNS. The claim must include the Product Identification Number (PIN) listed on the Formulary for the CGM being supplied.

<b>PIN</b>	<b>PIN Description</b>	<b>Manufacturer</b>
09858361	Dexcom G7® Receiver	Dexcom Canada, Co.

09858362	Dexcom G7® Sensor	Dexcom Canada, Co.
----------	-------------------	--------------------

Please refer to the Ontario Drug Programs Reference Manual for more information about standard claim submission requirements.

### **Recordkeeping**

Please refer to “Acceptable Supporting Documentation” in section 12 of the Ontario Drug Programs Reference Manual.

### **Requirements**

ODB program recipients who meet the Reimbursement Criteria summarized below are eligible for a maximum reimbursed quantity of Dexcom G7® Sensors over the course of a 365-day period as outlined in the table below:

<b>Reimbursement Criteria</b>	<b>Maximum reimbursed number of Dexcom G7® Sensors</b>
ODB program recipients managing diabetes with insulin	45 (one sensor lasts 10 days plus 12-hour grace period)

Dispensers must adhere to the reimbursement criteria and the maximum reimbursed quantity as noted above. Claims that do not meet these requirements may be subject to inspections and recovery where warranted.

The above information will be incorporated into the Ontario Drug Programs Reference Manual at a future date. In addition, the ministry intends to implement changes to the e-Formulary and the HNS related to the requirements at a future date. The requirements outlined above apply even though the changes to the e-Formulary and HNS have not yet been made.

**Additional Information:**

**For pharmacies:**

For billing inquiries, please call ODB Pharmacy Help Desk at: 1-800-668-6641

**For all other Health Care Providers and the Public:**

Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559. In Toronto, TTY 416-327-4282

All other inquiries should be directed to [DrugProgramsDelivery@ontario.ca](mailto:DrugProgramsDelivery@ontario.ca)